- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02195427
TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds
A Controlled, Randomized, Double-Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA Global Action and TEOSYAL® RHA Deep Lines Versus Juvéderm® Ultra XC in the Treatment of Moderate to Severe Nasolabial Folds
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
- United States, Alabama
-
-
California
-
Beverly Hills, California, United States
- United States, California
-
Santa Monica, California, United States
- United States, Santa Monica
-
-
Florida
-
Coral Gables, Florida, United States
- United States, Florida
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States
- United States, Massachusetts
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatient, male or female of any race, 22 years of age or older; female subjects of childbearing potential must have a negative urine pregnancy test and practice a reliable method of contraception
- NLFs classified as WSRS grade 3 or 4 (same score for each side)
- Willing to abstain from facial aesthetic procedures/therapies that could interfere with study evaluations
- Able to follow study instructions and likely to complete all required visits;
- Signed informed consent and HIPAA (Health Insurance Portability and Accountability Act) form
Exclusion Criteria:
- Female subjects that are pregnant or breast-feeding, or of childbearing potential and not practicing reliable birth control
- Known hypersensitivity/allergy to any component of the study devices
- Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, history of anaphylactic shock
- Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders
- Clinically significant active skin disease within 6 months
- History of active chronic debilitating systemic disease
- History of connective tissue disease
- History of malignancy (excl. non-melanoma skin cancer) within past 5 years
- History of bleeding disorders
- Need for clinically significant and continuous medical treatment within 2 weeks prior to first visit
- Received/used a prohibited treatment/procedure within certain time periods (e.g., bioresorbable fillers, NSAIDS, acetylsalicylic acid, high dose vitamin E, corticosteroids, interferon, anti-coagulation therapies, laser/light therapies, botulinum toxin injections (frontalis and glabella complex treatment permitted), prescription strength topical retinoids, facial peels, excisional facial surgery, clinically significant oral or maxillofacial surgery)
- Clinically significant alcohol or drug abuse, or history of poor cooperation, non-compliance with medical treatment, or unreliability
- Exhibit a physical attribute(s) that may prevent assessment or treatment of NLFs such as excessive facial hair, traumatic or surgical facial scars, and/or excessive hyperpigmentation in the treatment areas
- A condition or situation that may put the subject at significant risk, confound the study results, or significantly interfere with the subject participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TEOSYAL RHA Global Action/Juvederm Ultra XC
Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75).
Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis).
Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
|
A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant.
It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.
It is supplied in individual treatment syringes with 30G1/2" disposable sterile needles.
|
Experimental: TEOSYAL RHA Deep Lines/Juvederm Ultra XC
Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75).
Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis).
Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
|
A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant.
It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.
It is supplied in individual treatment syringes with 27G1/2" disposable sterile needles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-inferiority of the Delta of TEOSYAL® RHA GA and TEOSYAL® RHA DL Versus Juvéderm® Ultra XC for the Correction of Moderate to Severe NLFs Based on the Wrinkle Severity Rating Scale (WSRS) Score Assessed by the Blinded Live Evaluator (BLE).
Time Frame: Baseline and 24 weeks after last treatment
|
TEOSYAL® RHA GA = TEOSYAL® RHA Global Action TEOSYAL® RHA DL = TEOSYAL® RHA Deep Lines WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale assessing wrinkle severity with 1 being 'absent' and 5 being 'extreme' BLE = Blinded Live Evaluator
|
Baseline and 24 weeks after last treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post Injection Treatment Responses (From Common Treatment Responses (CTR) Diary) for Safety Evaluation of TEOSYAL® RHA Global Action (GA) and TEOSYAL® RHA Deep Lines (DL) Versus Juvéderm® Ultra XC (J).
Time Frame: During 14 days after initial treatment (D0) and touch-up (2 weeks)
|
The subjects received a diary booklet and instructions for recording his/her observations of the Common Treatment Responses of the study treatments for the first 14 days after each treatment (initial, touch-up). The diary was discussed during each telephone follow-up visit. Subjects should complete the diary at approximately the same time each day (i.e., am or pm). The subject diary captured the following Common Treatment Responses (CTR) that occur following the injection of a dermal filler; specifically, redness, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching, discoloration, and "other". The 14-day patient CTR diary included a detailed glossary describing all signs/symptoms listed in the diary; an option was provided to rate "other" if the subject experienced a sign/symptom that is not listed. The table presents the number of subjects experiencing at least 1 Common Treatment Response (CTR) |
During 14 days after initial treatment (D0) and touch-up (2 weeks)
|
Assessment of Injection Site Pain (Visual Analog Scale) of TEOSYAL® RHA Global Action (GA) and TEOSYAL® RHA Deep Lines (DL) Versus Juvéderm® Ultra XC (J).
Time Frame: During Injection and 5, 15, 30 minutes post-injection
|
VAS is a 100 mm Visual Analog Scale with 0 meaning no pain and 100 meaning intolerable pain
|
During Injection and 5, 15, 30 minutes post-injection
|
Delta of the WSRS Score Between W24,36,52 and Baseline for TEOSYAL® RHA GA Versus Juvéderm® Ultra XC and TEOSYAL® RHA DL Versus Juvéderm® Ultra XC for the Correction of Moderate to Severe NLFs Based on the WSRS Score Assessed by the BLE
Time Frame: Baseline and Weeks 24, 36, 52, 64
|
TEOSYAL® RHA GA = TEOSYAL® RHA Global Action TEOSYAL® RHA DL = TEOSYAL® RHA Deep Lines WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale assessing wrinkle severity with 1 being 'absent' and 5 being 'extreme' BLE = Blinded Live Evaluator
|
Baseline and Weeks 24, 36, 52, 64
|
Delta of the WSRS Score Between W2,4,12,24,36,52,64 and Baseline for TEOSYAL® RHA GA Versus Juvéderm® Ultra XC and TEOSYAL® RHA Deep Lines Versus Juvéderm® Ultra XC for the Correction of Moderate to Severe NLFs Based on the WSRS Score Assessed by the TI
Time Frame: Baseline and Weeks 2, 4, 12, 24, 36, 52, 64
|
TEOSYAL® RHA GA = TEOSYAL® RHA Global Action TEOSYAL® RHA DL = TEOSYAL® RHA Deep Lines WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale assessing wrinkle severity with 1 being 'absent' and 5 being 'extreme' TI = Treating Investigator
|
Baseline and Weeks 2, 4, 12, 24, 36, 52, 64
|
Percentage of Responders Based on the Intra-individual Improvement of at Least One Grade in the WSRS Compared to Baseline Assessed by the BLE
Time Frame: Baseline and Weeks 24, 36, 52, 64
|
A responder correspond to a subject with an intra-individual improvement of at least one grade in the WSRS compared to baseline
|
Baseline and Weeks 24, 36, 52, 64
|
Percentage of Responders Based on the Intra-individual Improvement of at Least One Grade in the WSRS Compared to Baseline Assessed by the TI
Time Frame: Baseline and Weeks 2, 4, 12, 24, 36, 52, 64
|
A responder correspond to a subject with an intra-individual improvement of at least one grade in the WSRS compared to baseline
|
Baseline and Weeks 2, 4, 12, 24, 36, 52, 64
|
Number of Subjects Scored Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Blinded Live Evaluator (BLE).
Time Frame: Weeks 24, 36, 52, 64
|
Global Aesthetic Improvement (GAI) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse" that evaluate the aesthetic improvement from baseline. GAI was assessed using the baseline photograph. Each side of the face was assessed independently. |
Weeks 24, 36, 52, 64
|
Number of Global Aesthetic Improvement (GAI) Responders (i.e., Scoring Either "Much Improved" or "Improved") on GAI Scale.
Time Frame: Weeks 4, 12, 24, 36, 52, 64
|
Global Aesthetic Improvement (GAI) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse" that evaluate the aesthetic improvement from baseline. GAI was assessed using the baseline photograph. Subjects will be instructed: "Use a mirror to compare your face to the photograph provided to you and rate the degree of aesthetic improvement by using the following scale". Each side of the face was assessed independently. |
Weeks 4, 12, 24, 36, 52, 64
|
Subject's Perception of Treatment Effectiveness as Per the FACE-Q (NLF Domain) Questionnaire
Time Frame: Immediately post-injection, and weeks 2, 4, 12, 24, 36, 52, 64
|
The FACE-Q measures the experience and outcomes of aesthetic facial procedures from the patient's perspective. FACE-Q questionnaire is composed of 5 questions with a score linked to answers (1 being 'Not at all' and 4 being 'Extremely'). The subject was instructed as follows: "These questions ask about how you look right now. With your nasolabial folds in mind (the deep lines that run downward from the sides of your nose), in the past week, how much have you been bothered by:", and provided response.
|
Immediately post-injection, and weeks 2, 4, 12, 24, 36, 52, 64
|
Subject's Satisfaction Score
Time Frame: Weeks 2, 4, 12, 24, 36, 52, 64
|
Subjective 5-point scale with 1 being 'very satisfied' and 5 being 'very dissatisfied'
|
Weeks 2, 4, 12, 24, 36, 52, 64
|
Volume to Obtain Optimal Cosmetic Result (Initial Treatment + Touch-up)
Time Frame: Week 2
|
Week 2
|
|
Number of Subjects Receiving Touch-up Treatment.
Time Frame: Week 2
|
Week 2
|
|
Number of Subjects Receiving Re-treatment
Time Frame: Weeks 24, 36, 52, 64
|
Weeks 24, 36, 52, 64
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TEO-RHA-1302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasolabial Folds, Wrinkles
-
Teoxane SAethica Clinical Research Inc.CompletedNasolabial Folds, WrinklesUnited States
-
Yung Shin Pharm. Ind. Co., Ltd.CompletedWrinkles Such as Nasolabial FoldsTaiwan
-
LG ChemActive, not recruiting
-
Galderma R&DCompletedWrinkles | Nasolabial FoldsCanada
-
Galderma R&DCompletedWrinkles | Nasolabial Folds | Marionette Lines
-
Erevna Innovations Inc.CompletedWrinkles Such as Nasolabial FoldsCanada
-
Genzyme, a Sanofi CompanyMentor Worldwide, LLCCompletedFacial Wrinkles at the Nasolabial FoldsUnited States
-
Kasiak Research Pvt. Ltd.UnknownFacial Wrinkles (Nasolabial Folds)India
-
Merz Pharmaceuticals GmbHCompletedSkin Diseases | Wrinkles | Physiological Stress | Nasolabial Folds | Disorder of AgingGermany
-
Samyang Biopharmaceuticals CorporationNot yet recruiting
Clinical Trials on TEOSYAL® RHA Global Action
-
Teoxane SAActive, not recruitingSkin Aging | Fine Lines of the Face and NeckSpain
-
Teoxane SAethica Clinical Research Inc.CompletedNasolabial Folds, WrinklesUnited States
-
Revance Therapeutics, Inc.Active, not recruiting
-
Teoxane SACompleted
-
Teoxane SARecruitingAging | Chin RetrusionSwitzerland
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | Varicella
-
Merck Sharp & Dohme LLCCompletedMeasles | Mumps | VaricellaFrance, Germany
-
Teoxane SACompletedCrow's Feet WrinklesSwitzerland